This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Mylan (MYL) Disappoint Investors This Earnings Season?
by Zacks Equity Research
During the Q4 earnings call, investors are expected to remain focused on the performance of Mylan's (MYL) EpiPen, newly launched drugs and the progress of the biosimilars pipeline.
United Therapeutics (UTHR) Q4 Earnings Decline on High Costs
by Zacks Equity Research
United Therapeutics' (UTHR) earnings per share decline in Q4 due to higher operating costs. Shares sink almost 10%.
Momenta's (MNTA) Earnings & Revenues Surpass Estimates in Q4
by Zacks Equity Research
Momenta (MNTA) delivers better-than-expected fourth-quarter results on the back of an upfront payment from CSL.
Teva's Problems Continue to Mount With No Relief in Sight
by Zacks Equity Research
Teva (TEVA) faces significant challenges including rapid erosion in sales of Copaxone and pricing erosion in the U.S. generics business.
J&J (JNJ) Gets FDA Nod for New Prostate Cancer Treatment (Revised)
by Zacks Equity Research
J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.
Here's Why Teva Pharma Stock Is Soaring Today
by Ryan McQueeney
Shares of Teva Pharmaceuticals (TEVA) gained more than 10% in early morning trading Thursday after news emerged Wednesday that Warren Buffett's Berkshire Hathaway (BRK.B) took a massive stake in the struggling drugmaker during the fourth quarter.
J&J (JNJ) Gets FDA Nod for New Prostrate Cancer Treatment
by Zacks Equity Research
J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.
Teva Stock Falls as Novartis Brings Another Copaxone Generic
by Zacks Equity Research
Teva's (TEVA) shares fall as Novartis launches the second generic version of the 40 mg formulation of Copaxone
Generic Drugmakers to Dump as Teva's Woes Continue in 2018
by Zacks Equity Research
The generic industry is facing several challenges pulling down several companies including Teva (TEVA).
Teva (TEVA) Q4 Earnings Top, Stock Tanks on Weak 2018 View
by Zacks Equity Research
Teva's (TEVA) fourth-quarter earnings and sales beat expectations. However, the 2018 sales and earnings outlook falls short of consensus estimate.
Teva (TEVA) Q4 Earnings & Sales Beat, 2018 View Disappoints
by Zacks Equity Research
Teva's (TEVA) fourth quarter earnings and sales beat expectations. However, the 2018 sales and earnings outlook falls short of consensus estimate. Stock crashes in pre-market trading.
What's in the Cards for Teva (TEVA) This Earnings Season?
by Zacks Equity Research
Teva's (TEVA) Generics segment sales are likely to be weak due to increased pricing erosion while loss of exclusivity of key drugs like Copaxone will hurt sales in the Specialty segment.
Teva Completes Sale of Women's Health Segment for $703M
by Zacks Equity Research
Teva Pharmaceutical (TEVA) sells woman health specialty products for cash consideration of $703 million.
Amgen's Migraine Drug Hits Primary Endpoint in Phase IIIb
by Zacks Equity Research
Amgen's (AMGN) antibody Aimovig meets all primary and secondary endpoints in a phase IIIb study on patients with episodic migraine, who have failed multiple prior preventive treatments.
Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies
by Zacks Equity Research
Teva's (TEVA) two phase III studies evaluating the subcutaneous formulation of its asthma injection, Cinqair (reslizumab) fail to meet primary endpoints.
Teva's Trisenox Gets FDA Approval as First-Line Treatment
by Zacks Equity Research
Teva Pharmaceutical (TEVA) receives approval from the FDA for label expansion of its leukemia drug, Trisenox, in first-line setting.
Parkinson's Disease Space Again Under Spotlight This Week
by Zacks Equity Research
Parkinson's Disease emerges a lucrative area in want of curative therapies in the space. To this end, many players work toward launching new treatments in the market.
AstraZeneca's Asthma Drug Benralizumab Gets Approval in EU
by Zacks Equity Research
AstraZeneca's (AZN) benralizumab receives approval in Europe as maintenance treatment for severe eosinophilic asthma under the trade name Fasenra.
Momenta & Mylan to Initiate Trial on Biosimilar of Eylea
by Zacks Equity Research
Momenta (MNTA), in collaboration with Mylan (MYL), plans to initiate a trial of M710, a proposed biosimilar of leading ophthalmology drug Eylea, in the first half of 2018.
New Strong Sell Stocks for December 20th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Teva's Migraine Candidate Gets Priority Review From FDA
by Zacks Equity Research
Teva's (TEVA) biologics license application (BLA) seeking approval for fremanezumab as a preventive treatment for migraine gets priority review from FDA
Bear of the Day: Mallinckrodt PLC (MNK)
by Kevin Cook
Generic drug makers are one of the worst performing industries this year and there's little sign of a turnaround
Teva's New CEO Re-Shuffles Senior Management, Stock Up 7%
by Zacks Equity Research
Teva (TEVA) announced several organizational changes in order to save costs and improve productivity.
Teva (TEVA) Stock Rises 5% on Reports of Massive Job Cuts
by Zacks Equity Research
Per an Israeli news release, Teva (TEVA) is expected to lay off 4000 employees
AstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDA
by Zacks Equity Research
AstraZeneca (AZN) received FDA approval for benralizumab for treating severe eosinophilic asthma.